The Filing Desk

Corcept Therapeutics vs Telix Pharmaceuticals

Corcept Therapeutics CORT · Telix Pharmaceuticals TLX · Pharmaceuticals

Telix Pharmaceuticals reported revenue of $804 million in fiscal 2025, about the same as Corcept Therapeutics' $761 million in fiscal 2025. Corcept Therapeutics' revenue grew 12.8% in its latest year, and Telix Pharmaceuticals' grew 55.6%. Corcept Therapeutics had an operating margin of 5.9%, against 3.7% at Telix Pharmaceuticals. Free cash flow was $142 million at Corcept Therapeutics and −$43 million at Telix Pharmaceuticals.

Side by side

Corcept TherapeuticsTelix Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$761M$804M
Revenue growth12.8%55.6%
Revenue growth a year, last 5 years16.6%—
Gross margin98.3%53.0%
Operating margin5.9%3.7%
Net margin13.1%−0.9%
Free cash flow$142M−$43M
Free cash flow margin18.6%−5.3%
Return on capital15.7%5.0%
Net debt to EBITDA−8.1x5.1x
Dividends and buybacks$173M$0M
Change in diluted share count5.7%−2.1%
Last close$64.98$8.71
P/E at the last close51.2×—
Insider trades, last 12 monthsbought $3.3 million, sold $93.4 millionbought $1.0 million, sold $0
Piotroski F-score3 of 92 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Corcept TherapeuticsTelix Pharmaceuticals
Operating margin
Percent of revenue
Corcept TherapeuticsTelix Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Corcept TherapeuticsTelix Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Corcept Therapeutics and Telix Pharmaceuticals pages.